Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions

Drug Discovery Today: Technologies

Volumn 11, Issue 1, 2014, Pages 11-18

  Diehl, Paul ^a   Tedesco, Donato ^a   Chenchik, Alex ^a  

^a Cellecta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; B RAF KINASE; BARDOXOLONE METHYL; CASPASE 10; CETUXIMAB; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 6; GEFITINIB; GEMCITABINE; GENOMIC DNA; INTERFERON REGULATORY FACTOR 4; K RAS PROTEIN; LENTIVIRUS VECTOR; PROTEIN MCL 1; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PAX8; VEMURAFENIB; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER CELL LINE; DNA DAMAGE; DNA REPAIR; DRUG DEVELOPMENT; DRUG SENSITIVITY; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LETHALITY; LOSS OF FUNCTION MUTATION; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; LYMPHOMA CELL; LYMPHOMA CELL LINE; MITOSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RNA ANALYSIS; RNA INTERFERENCE; DRUG RESISTANCE; GENETICS; NEOPLASM;

DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 84899984685     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2013.12.002     Document Type: Review

References (37)

1. T.R. Golub, D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, and J.P. Mesirov et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 238 1999 531 537
2. K. Chin, S. DeVries, J. Fridlyand, P.T. Spellman, R. Roydasgupta, K. Wen-Lin, and A. Lapuk et al. Genomic and transcriptional abberrations linked to breast cancer pathophysiologies Cancer Cell 10 2006 529 541
3. J. Barrentina, G. Caponigro, N. Stransky, K. Venkatesan, A. Margolin, and K. Sungjoon et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity Nature 483 2012 603 607
4. G. Ciriello, M.L. Miller, A. Aksoy, Y. Senbabaoglu, N. Schultz, and C. Sander Emerging landscape of oncogenic signature across human cancers Nat Genet 45 2013 11271133
5. M. Costanzo, A. Baryshnikaova, J. Bellay, Y. Kim, E.D. Spear, and C.S. Sevier et al. The genetic landscape of a cell Science 327 2010 425 431
6. O. Zuk, E. Hechter, S.R. Sunyaev, and E.S. Lander The mystery of missing heritability: genetic interactions create phantom heritability Proc Natl Acad Sci USA 109 2012 1193 1198
7. I.B. Weinstein Disorders in cell cicuitry during multistage carcinogenesis: the role of homeostasis Carcinogenesis 21 2000 857 864
8. H. Varmus The new era of cancer research Science 312 2006 1162 1165
9. D. Canaani Minireview: methodological approaches in application of synthetic lethality screening towards anticancer therapy Br J Cancer 100 2009 1213 1218
10. W.G. Kaelin Synthetic lethality: a framework for the development of wise cancer therapeutics Genome Med 1 2009 99
11. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibits for the treatment of cancers deficient in DNA double-strand repair J Clin Oncol 26 2008 3785 3790
12. H. Michiue, A. Eguchi, M. Scadeng, and S.F. Dowdy Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma Cancer Biol Ther 8 2009 2304 2311
13. S.M.B. Nijman Synthetic lethality: general principles, utility and detection using genetic screens in human cells FEBS Lett 585 2011 1 6
14. T. Sanda, J.W. Tyner, A. Gutierrez, V.N. Ngo, J. Glover, and B.H. Chang et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia Cancer Discov 3 2013 564 577
15. D. Sims, A.M. Mendes-Pereira, J. Frankum, D. Burgess, M. Cerone, and C. Lombardelli R.N.A. High-throughput interference screening using pooled shRNA libraries and next generation sequencing Genome Biol 12 2011 p. R104
16. R. Marcotte, K.R. Brown, F. Suarez, A. Sayad, K. Karamboulas, and P.M. Krzyzanowski et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells Cancer Discov 2 2012 172 189
17. C. Laufer, B. Fischer, M. Billmann, W. Huber, and M. Boutros Mapping genetic interactions in human cancer cells with RNAi and multiparametic phenotyping Nat Methods 10 2013 427 431
18. J.M. Silva, K. Marran, J.S. Parker, J. Silva, M. Golding, and M. Schlabach et al. Profiling essential genes in human mammary cells by multiplex RNAi screening Science 319 2008 617 620
19. B. Luo, H.W. Cheung, A. Subramanian, T. Sharifnia, M. Okamoto, and X. Yang et al. Highly parallel identification of essential genes in cancer cells Proc Natl Acad Sci USA 105 2008 20380 20385
20. C. Scholl, S. Froehling, I.F. Dunn, A.C. Schinzel, D.A. Barbie, and S.Y. Kim et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
21. C. Babij, Y. Zhang, R.J. Kurzeja, A. Munzli, A. Shehabeldin, and M. Fernando et al. STK33 kinase activity is nonessential in KRAS-dependant cancer cells Cancer Res 71 2011 5818 5826
22. I. Dussault, J. Carnahan, C. Babij, Y. Zhang, V. Watson, and K. Quon et al. STK33 kinase is not essential in KRAS-dependent cells-response Cancer Res 71 2011 p. 7717
23. A. Prahallad, C. Sun, S. Huang, F. Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600e) inhibition thorough feedback activation of EGFR Nature 483 2012 100 104
24. J. Fredebohm, J. Wolf, J.D. Hoheisel, and M. Boettcher Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine J Cell Sci 126 2013 3380 3389
25. Y. Qin, D. Wuguo, S. Ekmekcioglu, and E.A. Grimm Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening Pigment Cell Melanoma Res 26 2012 97 112
26. J.R. Mills, A. Malina, T. Lee, D. Di Paola, O. Larsson, and C. Miething et al. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eu-myc/Bcl-2 mouse model Blood 121 2013 3402 3412
27. C. Liu, D. van Dyk, Y. Li, B. Andrews, and H. Rao A genome-wide synthetic dosage lethality screen reveals multiple pathways that require the function of ubiquitin-binding proteins Rad23 and Dsk2 BMC Biol 7 2009 75
28. N. Dompe, C.S. Rivers, L. Li, S. Cordes, M. Schwickart, and E.A. Punnoose et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis Proc Natl Acad Sci USA 108 2011 E943 E951
29. M.R. Schlabach, J. Luo, N.L. Solimini, G. Hu, Q. Xu, and M.Z. Li et al. Cancer proliferation gene discovery through functional genomics Science 319 2008 620 624
30. A. Bommi-Reddy, I. Almeciga, J. Sawyer, C. Geisen, W. Li, and E. Harlow et al. Kinase requirements in human cells: Ill. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen Proc Natl Acad Sci USA 105 2008 16484 16489
31. H.W. Cheung, G.S. Cowley, B.A. Weir, J.S. Boehm, J.S. Rusin, and S. Rusin et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer Proc Natl Acad Sci USA 108 2011 12372 12377
32. R. Brough, J.R. Frankum, D. Sims, A. Mackay, A.M. Mendes-Pereire, and I. Bajrami et al. Functional viability profiles of breast cancer Cancer Discov 1 2011 260 273
33. D. Tedesco, M. Makhanov, K. Bonneau, P. Diehl, D. Deng, and A. Chenchik Identification of genes specific for viability of prostate cancer cells using a pooled lentiviral shRNA expression library Biotechniques 52 2012 198 199
34. S. Vicent, R. Chen, L.C. Sayles, C. Lin, R.G. Walker, and A.K. Gillespie et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models J Clin Invest 120 2010 3940 3952
35. L. Lamy, V.N. Ngo, N.C. Tolga Emre, A.L. Shaffer, Y. Yang, and E. Tian et al. Control of autophagic cell death by caspase-10 in multiple myeloma Cancer Cell 23 2013 435 449
36. A.L. Shaffer, N.C. Emre, L. Lamy, V.N. Ngo, G. Wright, and W. Xiao et al. IRF4 addiction in multiple myeloma Nature 454 2008 226 231
37. M.C. Bassik, M. Kampmann, R.J. Lebbink, S. Wang, M.Y. Hein, and I. Poser et al. A systematic mammalian genetic interation map reveals pathways underlying ricin susceptibility Cell 152 2013 1 14